Dissertation > Excellent graduate degree dissertation topics show

Effect of Rh-Endostatin on the Expression of ERCC1 in Human Lung Adenocarcinoma A549 Cells

Author: YanYan
Tutor: SunXiuHua
School: Dalian Medical University
Course: Oncology
Keywords: Lung Cancer Recombinant human endostatin Cisplatin ERCC1 A549 cells
CLC: R734.2
Type: Master's thesis
Year: 2011
Downloads: 26
Quote: 0
Read: Download Dissertation

Abstract


Lung cancer is gradually increased in recent years, the incidence of malignant tumors of various drug phenomenon greatly limits its clinical efficacy, so the genes involved in resistance and its mechanism of action will be to a large extent for the treatment of lung cancer to help. Cisplatin (DDP) is the clinical treatment of lung cancer one of the most commonly used chemotherapy drug, platinum-based drugs through the induction of tumor cell DNA damage caused by DNA replication disorder, and DNA repair systems can repair DNA damage caused by drugs, so that the body to produce anti- potency. The present study showed, ERCC1 gene expression and DDP resistance phenomenon intrinsically linked. Recombinant human endostatin (rh-Endostatin), trade name Endostar (Endostar), is China's first independently developed anti-angiogenic drugs, which in combination with chemotherapy drugs can increase the efficacy of chemotherapy, and this drug fewer side effects, good security. The experiment will be DDP, Endostar different modes of administration role in the human lung adenocarcinoma A549 cells, the drug treated cells mRNA expression of ERCC1 gene analysis. Objective: To investigate Endostar and DDP different modes of administration of human lung adenocarcinoma A549 cells ERCC1 gene expression, in order to provide theoretical guidance for second-line treatment of lung cancer. Methods: Human lung adenocarcinoma cell line A549 as the research object, the use of drugs for the DDP and Endostar. Were detected by MTT Endostar, DDP and DDP combination Endostar on A549 cell growth inhibition, and to determine the concentration of the drug used in the experiments. Logarithmic growth phase of the experiment were divided into four dosing groups, a control group, were: (1) DDP added in one (0.34μg/ml); (2) DDP minutes three days added (0.11 per day μg / ml); (3) DDP (0.34μg/ml), Endostar (300μg/ml) was added in one; (4) DDP minutes three days added (daily 0.11μg/ml), while added daily Endostar (300μg/ml ); (5) the control group. The grouping method according to the relevant drugs act on the cells, using Real Time PCR Detection of the treated cells relative expression of ERCC1mRNA. Results: 1.MTT method to get Endostar when the concentration of 300μg/ml, on A549 without significant cytotoxicity. DDP on A549 cells IC 30 is about 0.34μg/ml. When combined Endostar DDP on A549 cells IC 30 is about 0.13μg/ml. 2.Real Time PCR method derived cells ERCC1mRNA each experimental group relative expression levels were: ① 1.00; ② 0.88; ③ 2.00; ④ 1.90; ⑤ 0.77. Accordingly drawn: (1) dosing group were higher (2) were higher than the United Endostar DDP alone group. Conclusion: 1.Endostar increased DDP on human lung adenocarcinoma A549 cell cytotoxicity. 2.DDP and Endostar combination makes ERCC1mRNA A549 cells was significantly increased.

Related Dissertations

  1. The Clinical Research for the Effect of Iodine-125 Seeds Implanted in Advanced Bronchial Lung Cancer,R734.2
  2. Effects of 5-Aza-2-deoxycytidine on DNA Methylation and Expression of p16 and MGMT Gene in Lung Cancer Cell Line SPC-A-1,R734.2
  3. Methylation of p16 Gene in Plasma and Tissues from Non-small Cell Lung Cancer Patients, Demethylation and the Biological Behavior of Lung Cancer Cell and Transcription of p16 Gene,R734.2
  4. The Clinical Value of Detection of Serum TPS, CEA, CYFRA21-1, NSE for Diagnosis in Patients with Lung Cancer,R734.2
  5. Study on the Expression and Correlation of Metallothionein and Matrix Metalloproteinase-2 in Non-small Cell Lung Cancer,R734.2
  6. The Effect of RNA Interference-mediated ERCC1 Gene on the Chemo-treatment Sensitivity of NSCLC in Vitro,R734.2
  7. Non-small Cell Lung Cancer Analysis of 133 Cases of CVATS Lobectomy,R734.2
  8. Clinical Observation Pemetrexed Combined with Cisplatin As First-line Treatment of Advanced Lung Adenocarcinoma,R734.2
  9. Clinical Observation of Pemetrexed for Treating Advanced Non-small Cell Lung Cancer,R734.2
  10. Combined Detection of Tumor Markers in the Diagnosis and Treatment of Lung Cancer to Determine the Clinical Significance,R734.2
  11. Exploreing the Mechanism of Xieshifeiaifang Ii on Treating Lung Cancer with Pleura Effusion,R734.2
  12. The Analysis of the M8000/3 Coder of the Lung Cancer Case in a Hospital Between 2006 to 2010,R734.2
  13. Expression of Chemokine Receptor CCR5 in Human Non-small-cell Lung Cancer,R734.2
  14. Influence of NF-κB Inhibitor (PDTC) on Protein Expression of ASPP1 and ASPP2 of Non-small Cell Lung Cancer,R734.2
  15. Influences of Cisplatin on Expressions of P-glycoprotein in the Resistance Cells of in Lung Cancer Xenografts in the Mice,R734.2
  16. Study of the Reversal Effect of Recombinant Human Endostatin on Chemotherapy Resistance in Human Lung Adenocarcinoma A549/DDP Cells,R734.2
  17. Clinical Research on Detecing of the Combined Survivin mRNA with Cytokeratin 19(ck19) mRNA in Peripheral Blood of Non-small Cell Lung Cancer,R734.2
  18. The in Vitro Study of Serum-free Culture Combined DDP Enriching Human Lung Cancer Stem Cells,R734.2
  19. The Expression and Clinical Significance of Ercc1 in Human Gastric Cancer,R735.2
  20. Influence on NF-κB P65 and ASPP2 of Murine Lewis Lung Cancer of NF-кB Inhibitor PDTC and Cisplatin,R734.2

CLC: > Medicine, health > Oncology > Respiratory system tumors > Lung tumors
© 2012 www.DissertationTopic.Net  Mobile